Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Rachita K. Sumbria"'
Autor:
Nataraj Jagadeesan, G. Chuli Roules, Devaraj V. Chandrashekar, Joshua Yang, Sanjana Kolluru, Rachita K. Sumbria
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background Biologic TNF-α inhibitors (bTNFIs) can block cerebral TNF-α in Alzheimer’s disease (AD) if these macromolecules can cross the blood–brain barrier (BBB). Thus, a model bTNFI, the extracellular domain of type II TNF-α recepto
Externí odkaz:
https://doaj.org/article/9c7d4ce603b74672a7572a0c179d092c
Autor:
Devaraj V. Chandrashekar, G. Chuli Roules, Nataraj Jagadeesan, Urvashi R. Panchal, Adenike Oyegbesan, Oghenetega E. Imiruaye, Hai Zhang, Jerome Garcia, Kamaljit Kaur, Sanda Win, Tin A. Than, Neil Kaplowitz, Moom R. Roosan, Derick Han, Rachita K. Sumbria
Publikováno v:
Neurobiology of Disease, Vol 199, Iss , Pp 106570- (2024)
Background: Hepatic lipoprotein receptor-related protein 1 (LRP-1) plays a central role in peripheral amyloid beta (Aβ) clearance, but its importance in Alzheimer's disease (AD) pathology is understudied. Our previous work showed that intragastric a
Externí odkaz:
https://doaj.org/article/15f5f13e08d54a588a4da11e1312920d
Autor:
Hai Zhang, Rachita K. Sumbria, Rudy Chang, Jiahong Sun, David H. Cribbs, Todd C. Holmes, Mark J. Fisher, Xiangmin Xu
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-19 (2023)
Abstract Background Cerebral microhemorrhages (CMH) are associated with stroke, cognitive decline, and normal aging. Our previous study shows that the interaction between oxidatively stressed red blood cells (RBC) and cerebral endothelium may underli
Externí odkaz:
https://doaj.org/article/348c92fd4f674ca2add361badcf21756
Autor:
Chuo Fang, Wei Ling Lau, Jiahong Sun, Rudy Chang, Adrian Vallejo, Donghy Lee, Jihua Liu, Han Liu, Yu-Han Hung, Yitong Zhao, Annlia Paganini-Hill, Rachita K. Sumbria, David H. Cribbs, Mark Fisher
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-16 (2023)
Abstract Background Chronic kidney disease (CKD) is increasingly recognized as a stroke risk factor, but its exact relationship with cerebrovascular disease is not well-understood. We investigated the development of cerebral small vessel disease usin
Externí odkaz:
https://doaj.org/article/eafbdb1c3aab482e8b83e11404389a92
Autor:
Weijun Ou, Joshua Yang, Juste Simanauskaite, Matthew Choi, Demi M. Castellanos, Rudy Chang, Jiahong Sun, Nataraj Jagadeesan, Karen D. Parfitt, David H. Cribbs, Rachita K. Sumbria
Publikováno v:
Journal of Neuroinflammation, Vol 18, Iss 1, Pp 1-19 (2021)
Abstract Background Tumor necrosis factor-α (TNF-α) plays a central role in Alzheimer’s disease (AD) pathology, making biologic TNF-α inhibitors (TNFIs), including etanercept, viable therapeutics for AD. The protective effects of biologic TNFIs
Externí odkaz:
https://doaj.org/article/6e93ff10e37147479a9c27eeeef00f70
Autor:
Jerome Garcia, Rudy Chang, Ross A. Steinberg, Aldo Arce, Joshua Yang, Peter Van Der Eb, Tamara Abdullah, Devaraj V. Chandrashekar, Sydney M. Eck, Pablo Meza, Zhang-Xu Liu, Enrique Cadenas, David H. Cribbs, Neil Kaplowitz, Rachita K. Sumbria, Derick Han
Publikováno v:
Frontiers in Physiology, Vol 13 (2022)
Heavy alcohol consumption is a known risk factor for various forms of dementia and the development of Alzheimer’s disease (AD). In this work, we investigated how intragastric alcohol feeding may alter the liver-to-brain axis to induce and/or promot
Externí odkaz:
https://doaj.org/article/978cff4effb34625aa5b7e8bf5da6b13
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 11, p 9492 (2023)
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by cognitive impairment and memory loss. Epidemiological evidence suggests that heavy alcohol consumption aggravates AD pathology, whereas low alcohol intake may be p
Externí odkaz:
https://doaj.org/article/1162a1c9ed47434f8fb62a2b223704f7
Autor:
Joshua Yang, Weijun Ou, Nataraj Jagadeesan, Juste Simanauskaite, Jiahong Sun, Demi Castellanos, David H. Cribbs, Rachita K. Sumbria
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 558 (2023)
Erythropoietin (EPO), a hematopoietic neurotrophin, is a potential therapeutic for Alzheimer’s disease (AD) but has limited blood–brain barrier (BBB) permeability. EPO fused to a chimeric transferrin receptor monoclonal antibody (cTfRMAb) enters
Externí odkaz:
https://doaj.org/article/e5bc714831ce42149e79fdfeee5744f6
Publikováno v:
PLoS ONE, Vol 17, Iss 5 (2022)
Brain microvascular endothelial cells, forming the anatomical site of the blood-brain barrier (BBB), are widely used as in vitro complements to in vivo BBB studies. Among the immortalized cells used as in vitro BBB models, the murine-derived bEnd.3 c
Externí odkaz:
https://doaj.org/article/69bebfdf3e6b42af8b968ba58111d409
Autor:
Weijun Ou, Yuu Ohno, Joshua Yang, Devaraj V. Chandrashekar, Tamara Abdullah, Jiahong Sun, Riley Murphy, Chuli Roules, Nataraj Jagadeesan, David H. Cribbs, Rachita K. Sumbria
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2200 (2022)
Tumor necrosis factor alpha (TNF-α) plays a vital role in Alzheimer’s disease (AD) pathology, and TNF-α inhibitors (TNFIs) modulate AD pathology. We fused the TNF-α receptor (TNFR), a biologic TNFI that sequesters TNF-α, to a transferrin recept
Externí odkaz:
https://doaj.org/article/34dca426638a4e159188d71b07ae587d